Cargando…
BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13
Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist prop...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988860/ https://www.ncbi.nlm.nih.gov/pubmed/29203848 http://dx.doi.org/10.1038/mp.2017.220 |